Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies
Article Date
January 12, 2026
This article is featured on another website.
Go to article
July 14, 2026
Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate
July 14, 2026
Chime Biologics Congratulates Polpharma Biologics on Global Licensing Agreement with Teva for Ocrelizumab Biosimilar Candidate
June 5, 2026
Brain Tumors – Still an Area of Significant Unmet Need
The Challenge of Brain Tumors Brain tumors remain a serious challenge due to their complex…
June 5, 2026
Brain Tumors – Still an Area of Significant Unmet Need
The Challenge of Brain Tumors Brain tumors remain a serious challenge due to their complex…